<DOC>
	<DOCNO>NCT01376622</DOCNO>
	<brief_summary>Despite continuing advance iron chelation therapy , iron toxicity endocrine gland , particularly pituitary gland , remain common patient transfusion dependent anemia . We would like establish accurate population norm pituitary R2 volume understand progression pituitary iron transfuse patient Deferasirox .</brief_summary>
	<brief_title>Changes Pituitary Iron Volume With Deferasirox</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Currently chronic transfusion therapy . Duration chronic transfusion &gt; 1 year . Age 2 25 year On deferasirox monotherapy duration study . Informed consent legal guardian and/or patient . On deferasirox minimum 3 month start study . Sickle cell disease sicklebeta zero genotype . Combination deferasirox another iron chelator .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>